Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1

Interventions

Biopsy 17Specimen Handling 16Magnetic Resonance Spectroscopy 15Cyclophosphamide 14Rituximab 12obinutuzumab 8Lenalidomide 8fludarabine 7Prednisone 7pembrolizumab 6Nuclear Medicine Department, Hospital 6Doxorubicin 5glofitamab 4fludarabine phosphate 4X-Rays 4Vincristine 4Tacrolimus 4Mycophenolic Acid 4Etoposide 4Busulfan 4venetoclax 3trametinib 3sapanisertib 3ibrutinib 3copanlisib 3acalabrutinib 3Whole-Body Irradiation 3Nivolumab 3GSK2636771 3Crizotinib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma × ibritumomab tiuxetan × 30 days × Clear all
NCT00690560 2026-05-22

Combination Chemotherapy, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Newly Diagnosed Large B-Cell Lymphoma

Centre Antoine Lacassagne

Phase 2 Completed
30 enrolled 11 charts
Lymphoid

Lymphoma, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡